$VTVT News

vTv Therapeutics Inc. (NASDAQ:VTVT) Reports Massive Q1 Earnings Beat, But Stock Dips on "Sell the News" Reaction

vTv Therapeutics Q1 EPS $1.65 Beats $(0.10) Estimate, Sales $36.839M Beat $20.000M Estimate

vTv Therapeutics to Participate in Upcoming May Investor Conferences

Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Wall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a Bet

vTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin Advancements

Wall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to Trade

vTv Therapeutics to Participate in the 38th Annual ROTH Conference

Evercore ISI Group Initiates Coverage On vTv Therapeutics with Outperform Rating, Announces Price Target of $44

BTIG Reiterates Buy on vTv Therapeutics, Maintains $49 Price Target

VTv Therapeutics: Q4 Earnings Snapshot

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

vTv Therapeutics Q4 EPS $(0.58) Beats $(1.17) Estimate

vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737

VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst

vTv Therapeutics to Participate in Upcoming Investor Conferences

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

vTv Therapeutics Expands License Deal With Newsoara Biopharma To Offer Global Rights To PDE4 Inhibitor

BTIG Maintains Buy on vTv Therapeutics, Raises Price Target to $49